Smallpox DNA vaccine and the antigens therein that elicit an immune response
The present invention relates to DNA vaccines that are capable of generating a protective immune response in mammals against a pox virus, and comprises at least one DNA plasmid capable of expressing a plurality of VACV MV antigens, and at least one DNA plasmid capable of expressing a plurality of VACV EV antigens. Also, the present invention relates to methods of inducing a protective immune response in a mammal to pox virus, including a neutralizing antibody response, comprising: injecting into tissue of said mammal said DNA vaccine.
1. A method of inducing a protective immune response in a mammal to pox virus, including a neutralizing antibody response, comprising:
injecting into tissue of said mammal by intradermal injection a DNA vaccine comprising eight distinct DNA plasmids, wherein one DNA plasmid comprises a nucleotide sequence that encodes A4L, one DNA plasmid comprises a nucleotide sequence that encodes A27L, one DNA plasmid comprises a nucleotide sequence that encodes B5R, one DNA plasmid comprises a nucleotide sequence that encodes A33R, one DNA plasmid comprises a nucleotide sequence that encodes A56R, one DNA plasmid comprises a nucleotide sequence that encodes F9L, one DNA plasmid comprises a nucleotide sequence that encodes H3L, and one DNA plasmid comprises a nucleotide sequence that encodes L1R; and
electroporating said tissue with an electroporating amount of electrical energy.
2. The method of claim 1 , wherein the electroporating step comprises delivering a constant current to said tissue.
3. The method of claim 2 , wherein the electroporating step comprises delivering 0.2 A of current.
4. The method of claim 1 , further comprising repeating said injecting step and electroporating step.
5. The method of claim 1 , wherein the eight distinct DNA plasmids comprise: pGX4001, pGX4002, pGX4003, pGX4004, pGX4005, pGX4006, pGX4007, and pGX4008.
6. The method of claim 1 , wherein said method induces a protective immune response in a mammal to smallpox virus.
7. The method of claim 1 , wherein said nucleotide sequence that encodes A4L is SEQ ID NO: 1, said nucleotide sequence that encodes A27L is SEQ ID NO: 3, said nucleotide sequence that encodes B5R is SEQ ID NO: 5, said nucleotide sequence that encodes A33R is SEQ ID NO: 7, said nucleotide sequence that encodes A56R is SEQ ID NO: 9, said nucleotide sequence that encodes F9L is SEQ ID NO: 11, said nucleotide sequence that encodes H3L is SEQ ID NO: 13 (H3L), and said nucleotide sequence that encodes L1R is or SEQ ID NO: 15.
8. The method of claim 1 , wherein said A4L has the amino acid sequence of SEQ ID NO: 2, said A27L has the amino acid sequence of SEQ ID NO: 4, said B5R has the amino acid sequence of SEQ ID NO: 6, said A33R has the amino acid sequence of SEQ ID NO: 8, said A56R has the amino acid sequence of SEQ ID NO: 10, said F9L has the amino acid sequence of SEQ ID NO: 12, said H3L has the amino acid sequence of SEQ ID NO: 14 and said L1R has the amino acid sequence of SEQ ID NO: 16.
9. The method of claim 1 , wherein each of said DNA plasmids is present at a dose greater than 50 μg.
10. The method of claim 1 , wherein each of said DNA plasmids is present at a dose of 125 μg.
11. The method of claim 1 , further comprising administration of a nucleic acid sequence that encodes IL-8, IL-1 2 , IL-15, IL-18, IL-2 8 , MCP-1, MIP-1α, MIP-1p, RANTES, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, CTACK, TECK, or MEC, or a combination thereof.
12. The method of claim 1 , further comprising administration of a nucleic acid sequence that encodes IL-12, IL-15, IL-28, or RANTES.
13. The method of claim 5 , wherein each of said DNA plasmids is present at a dose of 125 μg.
14. A method of inducing a protective immune response in a mammal to pox virus, including a neutralizing antibody response, comprising:
injecting into tissue of said mammal by intradermal injection of a DNA vaccine comprising one or more plasmids that collectively comprise a nucleotide sequence that encodes VACV antigen A4L, a nucleotide sequence that encodes VACV antigen A27L, a nucleotide sequence that encodes VACV antigen B5R, a nucleotide sequence that encodes VACV antigen A33R, a nucleotide sequence that encodes VACV antigen A56R, a nucleotide sequence that encodes VACV antigen F9L, a nucleotide sequence that encodes VACV antigen H3L and a nucleotide sequence that encodes VACV antigen L1R, and
electroporating said tissue with an electroporating amount of electrical energy.
15. The method of claim 14 , wherein the electroporating step comprises delivering a constant current to said tissue.
16. The method of claim 15 , wherein the electroporating step comprises delivering 0.2 A of current.
17. The method of claim 14 , further comprising repeating said injecting step and electroporating step.
18. The method of claim 14 , wherein said nucleotide sequence that encodes A4L is SEQ ID NO: 1, said nucleotide sequence that encodes A27L is SEQ ID NO: 3, said nucleotide sequence that encodes B5R is SEQ ID NO: 5, said nucleotide sequence that encodes A33R is SEQ ID NO: 7, said nucleotide sequence that encodes A56R is SEQ ID NO: 9, said nucleotide sequence that encodes F9L is SEQ ID NO: 11, said nucleotide sequence that encodes H3L is SEQ ID NO: 13 and said nucleotide sequence that encodes L1R is or SEQ ID NO: 15.
19. The method of claim 18 , wherein each of said DNA plasmids is present at a dose of 125 μg.
20. The method of claim 14 , wherein said A4L has the amino acid sequence of SEQ ID NO: 2, said A27L has the amino acid sequence of SEQ ID NO: 4, said B5R has the amino acid sequence of SEQ ID NO: 6, said A33R has the amino acid sequence of SEQ ID NO: 8, said A56R has the amino acid sequence of SEQ ID NO: 10, said F9L has the amino acid sequence of SEQ ID NO: 12, said H3L has the amino acid sequence of SEQ ID NO: 14 and said L1R has the amino acid sequence of SEQ ID NO: 16.
21. The method of claim 14 , wherein said method induces a protective immune response in a mammal to smallpox virus.